CHICAGO -- A study by actuaries at the SOA Research Institute found GLP-1s and insulin are cost effective when compared with no treatment at all, with GLP-1s offering a higher cost savings, particularly if rebates are factored in. The findings come as lawmakers and policymakers point to high GLP-1 and insulin costs in their calls to lower prescription drug costs. “What we determined was that GLP-1s and insulin were the most cost-effective treatments, but without the rebates included, the cost...